Healyx Changes Lives by Treating Chronic Wounds

Lower-cost, more-effective treatments are the hallmark of many Fogarty Institute companies, and that is the principle Healyx is living up to with its device that provides gold standard care for a chronic problem at a significant cost reduction.

Non-healing wounds are a critical global issue, with over eight million Medicare patients afflicted at an annual cost of $31.7 billion in the U.S.

Stanford Neurosurgeon and Entrepreneur Inspires Audience at 20th Annual Fogarty Lecture

This year’s annual Thomas J. Fogarty Lecture marked a milestone with the celebration of its 20thanniversary. The series, hosted by Stanford Biodesign and co-sponsored by the Fogarty Institute, started as a gathering to discuss and promote medical innovation with approximately 30 people in attendance. Since then, it has grown into a preeminent opportunity to learn from the most notable innovators in health technology.

Alydia Health Raises $10M in Series B Financing; Company Aims to Eradicate PPH Globally

Fogarty Institute graduate Alydia Health, formerly known as InPress Technologies, is well on its way to conducting a pivotal study, thanks to the closing of a recent $10M Series B round led by Global Health Investment Fund. The U.S. study aims to prove the safety and efficacy of its novel device, the Jada System, in stopping postpartum hemorrhage (PPH) —

Q&A With Holly Rockweiler, CEO and Co-Founder of Madorra

A former Stanford Biodesign Fellow and Fogarty Institute entrepreneur, 32-year-old Holly Rockweiler has already had remarkable accomplishments early in her career, fluently moving her startup to the next level.

Most notably, Holly has parlayed Madorra’s impressive study results into securing funding, including winning several pitching competitions, despite the chronically challenging medtech fundraising environment.

Spotlight: Ridhi Tariyal, Ferolyn Fellow

Each year, the caliber of professionals who participate in the Ferolyn Fellowship continues to impress us. Hailing from diverse parts of the healthcare spectrum, they all share an undeniable passion for the medtech industry, coupled with curiosity and the tenacity to solve large problems. In addition, it’s clear that they desire to be part of a community committed to not only accelerating their own career path,

New Fogarty Institute Company Lume Medical Developing a Large Bore Vascular Closure Device, a Key Benefit to Cardio Patients

When a cardiovascular intervention is called for, a less-invasive solution is always preferred – which is why percutaneous procedures, such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR) are on the rise.

But this trend hasn’t been without its drawbacks, as cardiologists and surgeons are now faced with the challenge of closing relatively large femoral access sites – ranging from three to eight millimeters in size – that are required to conduct these procedures.

12

START TYPING AND PRESS ENTER TO SEARCH